In the quiet districts of West Bengal, a spectre from the past has returned to haunt the present. After a hiatus of nearly two decades, the Nipah virus (NiV)—a pathogen known for its terrifyingly high fatality rate and lack of specific treatment—has re-emerged. In January 2026, health authorities confirmed that the virus had breached the state’s borders once again, marking the first outbreak in West Bengal in 19 years. This resurgence, coupled with recurrent outbreaks in Kerala, has reignited a global conversation about zoonotic spillover, hospital safety, and the urgent, high-stakes race for a vaccine.

The situation is fluid and critical. Two healthcare workers, nurses at a private hospital in Barasat on the outskirts of Kolkata, have been admitted to intensive care, battling the severe encephalitis that characterises the later stages of the disease. Their infection serves as a grim reminder of the virus's ability to jump not just from animals to humans, but from patient to caregiver. As the National Centre for Disease Control (NCDC) and the Indian Council of Medical Research (ICMR) mobilise rapid response teams, the question on everyone’s mind is: Are we ready for Nipah?

The West Bengal Mystery: A 19-Year Slumber Broken

For nearly twenty years, West Bengal believed it had seen the last of Nipah. The state suffered devastating outbreaks in 2001, where 45 people died, and again in 2007, which claimed five lives. Since then, the virus seemed to have shifted its geographical focus to southern India, specifically Kerala, which has battled almost annual outbreaks between 2018 and 2025. However, the discovery of confirmed cases in early 2026 has shattered that illusion of safety.

The current cases in North 24 Parganas have triggered a high alert. Preliminary investigations suggest the infected healthcare workers may have contracted the virus during a visit to Purba Bardhaman, although the exact chain of transmission remains a subject of intense epidemiological scrutiny. This ambiguity is characteristic of Nipah; the "source patient" or index case is often difficult to identify until extensive contact tracing is complete.

What makes the West Bengal resurgence particularly concerning is the lack of recent institutional memory in handling the virus compared to Kerala. While Kerala has developed a robust protocol due to its repeated encounters with the pathogen—implementing isolation zones, route maps, and rapid testing—West Bengal is essentially restarting its containment engine after a generation. The Union Health Ministry has deployed a national joint outbreak response team to support the state, focusing on tracing every individual who may have come into contact with the infected nurses.

Understanding the Enemy: What is Nipah Virus?

To understand the fear Nipah instils, one must understand its biology. Nipah virus is a paramyxovirus, a cousin of the measles and mumps viruses, but far more lethal. It is a zoonotic virus, meaning it is transmitted from animals to humans. The primary natural reservoir for Nipah is the fruit bat of the genus Pteropus, often called the flying fox. These bats are endemic across South and Southeast Asia, carrying the virus without falling ill themselves.

The World Health Organisation (WHO) classifies Nipah as a priority pathogen because of its epidemic potential. Unlike COVID-19, which spreads with terrifying speed but has a relatively low case fatality rate, Nipah moves slower but kills efficiently. Mortality rates in past outbreaks have ranged from 40 per cent to a staggering 75 per cent. In some localized clusters, it has killed every person it infected.

The virus attacks the body on two fronts. It can cause severe respiratory distress, similar to atypical pneumonia, and it can infect the brain, causing acute encephalitis (inflammation of the brain). This dual attack profile makes clinical management incredibly difficult, as patients can deteriorate rapidly from a mild fever to a coma within 24 to 48 hours.

The Transmission Web: Bats, Sap, and Humans

The ecology of Nipah transmission is a fascinating but deadly interplay between nature and culture. In the context of Bangladesh and West Bengal, the primary route of spillover from bats to humans is the consumption of raw date palm sap.

In rural areas, it is a winter tradition to place clay pots on date palm trees overnight to collect the sweet sap. Unfortunately, fruit bats also love this sugary treat. As they drink from the pots or the shaved part of the tree, they may urinate or defecate into the collection vessel, or lick the sap, contaminating it with saliva. When humans drink this raw, fresh sap the next morning—often as a delicacy called ‘toddy’—they ingest the virus directly.

This route of transmission explains the seasonality of outbreaks in this region, which almost always occur during the winter and spring sap-harvesting months. However, the threat does not stop there. Once a human is infected, the virus can spread to others.

Human-to-Human Transmission

This secondary transmission is what keeps virologists awake at night. Human-to-human spread has been regularly documented in India and Bangladesh, particularly within families of patients and, crucially, in healthcare settings. The current situation in Kolkata involving nurses highlights the risk of nosocomial (hospital-acquired) infection. Bodily fluids—including saliva, urine, and respiratory droplets—of an infected patient are highly contagious during the acute phase of the illness.

In the terrifying Siliguri outbreak of 2001, a significant number of infections occurred among hospital staff and visitors who were exposed to undiagnosed patients. This ability to spread in hospitals turns healthcare facilities from places of healing into amplification centres for the outbreak.

Symptoms: The Clinical Progression

Identifying Nipah early is a challenge because its initial symptoms mimic common influenza. Patients typically present with:

• High fever
• Headaches
• Myalgia (muscle pain)
• Vomiting
• Sore throat

Because these symptoms are non-specific, they can easily be mistaken for flu, dengue, or even COVID-19. However, the disease progression in Nipah is often rapid and severe. Following the initial febrile phase, patients may experience dizziness, drowsiness, and altered consciousness. These are the warning signs of encephalitis.

In severe cases, the neurological decline is precipitous. Patients can suffer from seizures and slip into a deep coma within a day or two of the onset of neurological signs. Some patients also develop severe respiratory distress, struggling to breathe as their lungs succumb to atypical pneumonia.

Even for those who survive, the battle may not be over. Approximately 20 per cent of survivors are left with long-term neurological sequelae, such as persistent seizure disorders or personality changes. Furthermore, there is a phenomenon known as "relapsed encephalitis," where a survivor who has apparently recovered falls ill again months or even years later as the virus reactivates in the brain.

The Treatment Void

Perhaps the most frightening aspect of Nipah virus infection is the lack of a cure. Currently, there are no drugs or vaccines specifically approved for use against Nipah virus in humans. The U.S. Food and Drug Administration (FDA) and other global regulatory bodies have yet to authorise a specific therapeutic intervention.

Treatment is purely supportive. This means doctors focus on keeping the patient alive while their immune system fights the virus. This involves managing fever, keeping the patient hydrated, and, in severe cases, using mechanical ventilation to assist with breathing. Ribavirin, an antiviral drug, has been used in some outbreaks, but its efficacy remains unproven and controversial. Monoclonal antibodies, such as m102.4, have been used on a compassionate basis in some cases, but they are not widely available or licensed for general use.

The Global Race for a Vaccine

While the current therapeutic landscape is bleak, the future holds significant promise. The scientific community, shaken by the pandemic potential of Nipah, has accelerated efforts to develop a vaccine. Leading the charge is the Coalition for Epidemic Preparedness Innovations (CEPI), which has funded multiple candidates.

The Oxford Candidate: ChAdOx1 NipahB

In a major breakthrough, the University of Oxford launched the world's first Phase II clinical trial of a Nipah virus vaccine in late 2025. The candidate, known as ChAdOx1 NipahB, utilises the same viral vector platform that was successfully used for the Oxford/AstraZeneca COVID-19 vaccine. This technology uses a harmless chimpanzee adenovirus to deliver genetic instructions for the Nipah virus spike protein to the body, training the immune system to recognise the threat.

The trials are currently underway in Bangladesh, a country that bears the brunt of annual outbreaks. This location is strategic; testing the vaccine in an endemic region ensures that researchers can assess its efficacy in a real-world setting where the virus is actively circulating. Early data from Phase I trials and animal studies have been promising, showing that the vaccine generates a robust immune response and protects against lethal infection.

mRNA Technology

Following the success of mRNA vaccines during the COVID-19 pandemic, this technology is also being applied to Nipah. Companies like Moderna and Gennova Biopharmaceuticals are developing mRNA-based candidates. Gennova, based in Pune, India, is collaborating with international partners to create a self-amplifying mRNA vaccine. These vaccines work by teaching our cells how to make a protein that triggers an immune response, offering a potentially rapid and adaptable solution to outbreaks.

Mathematical Modelling and Control Strategies

Beyond biology, mathematics plays a crucial role in containing Nipah. Epidemiologists use mathematical models to calculate the basic reproduction number (R0), which indicates how many people one infected person will spread the virus to. In the absence of control measures, if the R0 is greater than one, the outbreak grows.

Recent studies modelling Nipah transmission dynamics suggest that optimal control strategies—specifically isolation and the protection of healthcare workers—are vital. Simulations show that while the virus is highly lethal, its transmission can be curbed effectively if the contact rate between infected individuals and the susceptible population is minimised immediately. This reinforces the need for the rigorous contact tracing currently being undertaken in West Bengal and Kerala. The data indicates that reducing the transmission rate in hospital settings (nosocomial transmission) is the single most effective way to flatten the curve of a Nipah outbreak.

Prevention: The One Health Approach

Until a vaccine is widely available, prevention remains our only shield. This requires a "One Health" approach, which recognises that human health is interconnected with animal health and the environment.

Safe Practices with Date Palm Sap: Health authorities in India and Bangladesh have long campaigned against drinking raw date palm sap. The recommendation is simple: boil the sap before consumption. Boiling kills the virus instantly. Furthermore, farmers are encouraged to use bamboo skirts or nets to cover the collection pots, preventing bats from accessing the sap.

Fruit Hygiene: Since bats also feed on fruits, partially eaten fruits found on the ground should never be consumed. Thoroughly washing and peeling fruits is a standard precaution that can reduce the risk of exposure to bat saliva.

Healthcare Precautions: For healthcare workers, standard infection control precautions are non-negotiable when dealing with patients suspected of acute encephalitis. This includes the use of full Personal Protective Equipment (PPE), isolation of suspected cases, and rigorous hand hygiene. The infection of the nurses in the current West Bengal outbreak serves as a tragic reminder that any lapse in protocol can be fatal.

The Current Situation in India (2025-2026)

The resurgence in West Bengal is occurring against a backdrop of continued activity in Kerala. In mid-2025, Kerala reported four confirmed cases, including fatalities, across Malappuram and Palakkad districts. The efficiency of Kerala’s response—involving route maps, isolation wards, and the testing of hundreds of contacts—has prevented these clusters from spiralling into larger epidemics.

However, the detection of Nipah antibodies in bat populations across other states, including Karnataka, Tamil Nadu, Telangana, and Odisha, suggests that the risk is not confined to Kerala and Bengal. The virus is present in the natural reservoir across a wide swath of the subcontinent. As climate change and deforestation push bats closer to human settlements, the frequency of spillover events is predicted to rise.

Conclusion: Vigilance is the Vaccine

The return of Nipah to West Bengal after nineteen years is a wake-up call. It reminds us that zoonotic threats do not disappear; they merely retreat into the wild, waiting for the next opportunity to spill over. While the fatality rates are terrifying, history has shown that Nipah outbreaks can be contained through swift public health action, community awareness, and the bravery of healthcare workers.

The ongoing vaccine trials in Bangladesh and the UK offer a glimmer of hope on the horizon. We are closer than ever to having a pharmaceutical shield against this deadly virus. But until that day arrives, our best defence remains vigilance—boiling the sap, washing the fruit, and maintaining the highest standards of hygiene in our hospitals. The virus may be silent, but our response must be loud, coordinated, and relentless.